The Lancet published the results of the University of Oxford's Phase 1/2 in a vaccine trial. The editor of the highly regarded medical publication has tweeted that the vaccine is safe, well-tolerated, and immunogenic.
The research is done in collaboration with AstraZeneca and the UK secured around 90 million doses of the candidate, ahead of a broader trial. Apart from creating antibodies, it also triggers the creation of T-cells. This development was previously described as "double-protection."
-- more to come
The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging. https://t.co/oQp2eoZYIg— richard horton (@richardhorton1) July 20, 2020
Administering the vaccine candidate triggered antibody responses in 32/35 (91%) participants after a single dose. After a booster dose, all participants had neutralizing activity.
The S&P 500 has turned positive after kicking off marginally lower at the beginning of a new trading week. Moderna and Pfizer/NioNTech.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.